JP6543259B2 - 選択的ｎｒ２ｂアンタゴニスト - Google Patents

選択的ｎｒ２ｂアンタゴニスト Download PDF

Info

Publication number
JP6543259B2
JP6543259B2 JP2016545819A JP2016545819A JP6543259B2 JP 6543259 B2 JP6543259 B2 JP 6543259B2 JP 2016545819 A JP2016545819 A JP 2016545819A JP 2016545819 A JP2016545819 A JP 2016545819A JP 6543259 B2 JP6543259 B2 JP 6543259B2
Authority
JP
Japan
Prior art keywords
fluoro
piperidin
pyrrolidin
hydroxyphenyl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016545819A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017502063A5 (und
JP2017502063A (ja
Inventor
ダルトン・キング
ロリン・エイ・トンプソン・ザ・サード
ジャンリアン・シ
スリニバサン・タンガティルパティ
ジャヤクマール・サンカラ・ウォリアー
イマドゥル・イスラム
ジョン・イー・マコー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2017502063A publication Critical patent/JP2017502063A/ja
Publication of JP2017502063A5 publication Critical patent/JP2017502063A5/ja
Application granted granted Critical
Publication of JP6543259B2 publication Critical patent/JP6543259B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
JP2016545819A 2014-01-09 2015-01-06 選択的ｎｒ２ｂアンタゴニスト Expired - Fee Related JP6543259B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461925363P 2014-01-09 2014-01-09
US61/925,363 2014-01-09
PCT/US2015/010262 WO2015105772A1 (en) 2014-01-09 2015-01-06 Selective nr2b antagonists

Publications (3)

Publication Number Publication Date
JP2017502063A JP2017502063A (ja) 2017-01-19
JP2017502063A5 JP2017502063A5 (und) 2018-02-08
JP6543259B2 true JP6543259B2 (ja) 2019-07-10

Family

ID=52463126

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016545819A Expired - Fee Related JP6543259B2 (ja) 2014-01-09 2015-01-06 選択的ｎｒ２ｂアンタゴニスト

Country Status (27)

Country Link
US (10) US9221796B2 (und)
EP (1) EP3092224B1 (und)
JP (1) JP6543259B2 (und)
KR (1) KR102311518B1 (und)
CN (1) CN106061961B (und)
AR (1) AR099071A1 (und)
AU (1) AU2015205001A1 (und)
CA (1) CA2936293A1 (und)
CL (1) CL2016001763A1 (und)
DK (1) DK3092224T3 (und)
EA (1) EA201691413A1 (und)
ES (1) ES2693250T3 (und)
HR (1) HRP20181585T1 (und)
HU (1) HUE041986T2 (und)
IL (1) IL246599A0 (und)
LT (1) LT3092224T (und)
MX (1) MX2016008898A (und)
PE (1) PE20160933A1 (und)
PL (1) PL3092224T3 (und)
PT (1) PT3092224T (und)
RS (1) RS57830B1 (und)
SG (1) SG11201605618WA (und)
SI (1) SI3092224T1 (und)
TR (1) TR201815579T4 (und)
TW (1) TWI640515B (und)
UY (1) UY35947A (und)
WO (1) WO2015105772A1 (und)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9221796B2 (en) * 2014-01-09 2015-12-29 Bristol-Myers Squibb Company Selective NR2B antagonists
JP6938485B2 (ja) 2015-10-14 2021-09-22 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 選択的ｎｒ２ｂアンタゴニスト
CA3001894A1 (en) * 2015-10-14 2017-04-20 Bristol-Myers Squibb Company Selective nr2b antagonists
CN108203404A (zh) * 2018-03-02 2018-06-26 上海博邦医药科技有限公司 (r)-3-苯基哌啶或/和(s)-3-苯基哌啶以及尼拉帕尼的手性中间体的合成方法
US10781172B2 (en) 2018-06-21 2020-09-22 Northwestern University Catalysts and methods for enantioselective conjugate additions of amines to unsaturated electrophiles

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2744448B1 (fr) 1996-02-02 1998-04-24 Pf Medicament Nouvelles piperidines derivees d'aryl piperazine, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
AU3818900A (en) 1999-04-14 2000-11-02 F. Hoffmann-La Roche Ag Process for the preparation of substituted piperidines
US6476041B1 (en) 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
CZ20023479A3 (cs) 2000-04-26 2003-04-16 Warner-Lambert Company Cyklohexylaminový derivát, jako subtyp selektivních antagonistů NMDA receptoru
JPWO2003035641A1 (ja) 2001-10-22 2005-02-10 塩野義製薬株式会社 新規カルバモイルピロリドン誘導体
JP3927228B2 (ja) 2003-06-04 2007-06-06 メルク エンド カムパニー インコーポレーテッド Ｎｍｄａ／ｎｒ２ｂ拮抗物質としての３−フルオロ−ピペリジン
BRPI0415113A (pt) 2003-10-08 2006-11-28 Pfizer compostos de lactama condensados
EP2520567A3 (en) 2006-02-23 2012-12-12 Shionogi & Co., Ltd. Nitrogen-containing heterocycle derivatives substituted with cyclic group
CN103497114A (zh) * 2007-06-29 2014-01-08 埃莫里大学 用于神经保护的nmda受体拮抗剂
US9221796B2 (en) * 2014-01-09 2015-12-29 Bristol-Myers Squibb Company Selective NR2B antagonists

Also Published As

Publication number Publication date
US20210121453A1 (en) 2021-04-29
US9221796B2 (en) 2015-12-29
HRP20181585T1 (hr) 2018-12-14
CN106061961A (zh) 2016-10-26
PT3092224T (pt) 2018-11-14
RS57830B1 (sr) 2018-12-31
EP3092224A1 (en) 2016-11-16
KR20160105885A (ko) 2016-09-07
LT3092224T (lt) 2018-10-25
HUE041986T2 (hu) 2019-06-28
KR102311518B1 (ko) 2021-10-08
AU2015205001A1 (en) 2016-08-18
DK3092224T3 (en) 2018-11-26
EP3092224B1 (en) 2018-08-22
US20200163949A1 (en) 2020-05-28
US20180000807A1 (en) 2018-01-04
US20190117638A1 (en) 2019-04-25
CN106061961B (zh) 2018-12-18
UY35947A (es) 2015-07-31
MX2016008898A (es) 2016-10-04
SG11201605618WA (en) 2016-08-30
JP2017502063A (ja) 2017-01-19
SI3092224T1 (sl) 2018-11-30
PE20160933A1 (es) 2016-09-10
CL2016001763A1 (es) 2017-02-10
US20190314358A1 (en) 2019-10-17
TW201613884A (en) 2016-04-16
WO2015105772A1 (en) 2015-07-16
US20160081995A1 (en) 2016-03-24
AR099071A1 (es) 2016-06-29
US20180250283A1 (en) 2018-09-06
US20180110766A1 (en) 2018-04-26
IL246599A0 (en) 2016-08-31
US20150191452A1 (en) 2015-07-09
PL3092224T3 (pl) 2019-05-31
EA201691413A1 (ru) 2016-10-31
ES2693250T3 (es) 2018-12-10
TWI640515B (zh) 2018-11-11
TR201815579T4 (tr) 2018-11-21
CA2936293A1 (en) 2015-07-16
US20170258777A1 (en) 2017-09-14

Similar Documents

Publication Publication Date Title
JP6543259B2 (ja) 選択的ｎｒ２ｂアンタゴニスト
CA2777041A1 (en) Pyrrolidine gpr40 modulators
JP6843853B2 (ja) 選択的ｎｒ２ｂアンタゴニスト
JP6629738B2 (ja) 精神障害の治療のための（ｒ）−３−（（３ｓ，４ｓ）−３−フルオロ−４−（４−ヒドロキシフェニル）ピペリジン−１−イル）−１−（４−メチルベンジル）ピロリジン−２−オンおよびそのプロドラッグ
ES2668873T3 (es) Compuestos de indazol como agonistas del receptor 5-ht4
JP6938485B2 (ja) 選択的ｎｒ２ｂアンタゴニスト

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171225

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180816

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180821

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181227

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190521

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190614

R150 Certificate of patent or registration of utility model

Ref document number: 6543259

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees